Hampered glucose utilization might be attributed to abnormal insulin secretion and insulin resistance because the expression levels of genes involved in insulin secretion or insulin resistance, such as CFTR8, ins, and cyp17a1 (Table S6, details of the particular genes mentioned below are found in Table S6), were found to be disturbed in the TPhP-treated groups37, 38. The gene discussed is CYP17A1; the disease is Insulin resistance.